Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 3 7Phase 1/2 5Phase 1 4Phase 2/3 2Phase NA 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Hematologic Neoplasms 2Recurrence 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Tumors 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 222Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Homoharringtonine × Clear all
NCT04926285 2026-03-16

VEN-OM

University of Illinois at Chicago

Phase 1 Completed
6 enrolled
Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

NCT02141477 2018-02-13

Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

M.D. Anderson Cancer Center

Phase 1 Terminated
2 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT01844869 2015-01-30

An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
6 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT00675350 2014-05-12

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
12 enrolled

Hematologic Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡